Effect of Phytoecdysterone Administration in Subjects With Prediabetes

PreDiabetes Clinical Trial

Official title: Effect of Phytoecdysterone Administration on Cytotoxicity, Genotoxicity and Metabolic Control in Subjects With Prediabetes

Status Recruiting

Clinical Trial Summary

Prediabetes is the term used for people whose glucose levels do not meet the criteria for diabetes but are too high to be considered normal. This is defined by the presence of blood glucose between 100-125 mg / dL, values per glucose tolerance curve of 140-199mg / dL and/or HbA1c 5.7-6.4%. Prediabetes should not be considered as a clinical entity in itself, but as a risk factor for diabetes and cardiovascular disease (CVD). Prediabetes is associated with obesity (especially abdominal or visceral obesity), dyslipidemia with elevated triglycerides and/or low HDL cholesterol, and hypertension.

Clinical Trial Description

Subjects with a diagnosis of prediabetes are included according to the criteria of the American Diabetes Association in its version 2019, between 30 and 60 years old residents of the city of Guadalajara, Jalisco, Mexico who come to clinical nutrition consultation in the University Hospital Fray Antonio Alcalde from the city of Guadalajara, Jalisco, Mexico.

The study design is a randomized, randomized clinical trial with a control group in two groups: an intervention group with ecdysterone 300mg every 24 hours for 12 weeks (approximately 90 days) and an approved placebo control group (magnesia stearate) ) at 300mg every 24 hours for 12 weeks (approximately 90 days). ;

Related Conditions & MeSH terms

• Glucose Intolerance
• PreDiabetes
• Prediabetic State

• NCT number: NCT03906201
• Study type: Interventional
• Source: University of Guadalajara
• Contact: ANA FLETES
• Phone: 011521-3310585200
• Email: anna.fletes@gmail.com
• Status: Recruiting
• Phase: N/A
• Start date: February 6, 2019
• Completion date: July 31, 2020